In in vitro and in vivo studies by Stasenko et al., the results revealed that the anti-Gal-3 blockade inhibits AKT and ERK1/2 phosphorylation in MUC16-expressing cancer cell lines, impeding their invasive abilities and prolonging the overall survival of tumor-bearing mice [92]. This evidence concerns the gene LGALS3 and cancer.